Vistagen Therapeutics, Inc. (VTGN)

Market Cap	87.12M
Revenue (ttm)	971,000
Net Income (ttm)	-33.19M
Shares Out	27.06M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	431,327
Open	3.110
Previous Close	3.110
Day's Range	3.070 - 3.260
52-Week Range	2.450 - 5.860
Beta	0.78
Analysts	Strong Buy
Price Target	13.50 (+319.26%)
Earnings Date	Nov 7, 2024

About VTGN

Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company’s product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spra...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: VTGN
• Website: https://www.vistagen.com

Analyst Forecast

According to 2 analysts, the average rating for VTGN stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 319.26% from the latest price.

Price Target

$13.5

(319.26% upside)

Analyst Consensus: Strong Buy